Jay D Horton

List of Publications by Year
in descending order

50 papers	26,299 citations	101543 36 h-index	206112 48 g-index
52 all docs	52 docs citations	52 times ranked	27971 citing authors

#	Article	IF	Citations
1	SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. Journal of Clinical Investigation, 2002, 109, 1125-1131.	8.2	3,528
2	Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology, 2004, 40, 1387-1395.	7.3	3,250
3	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2017, 38, 2459-2472.	2.2	2,292
4	SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. Journal of Clinical Investigation, 2002, 109, 1125-1131.	8.2	2,177
5	Human Fatty Liver Disease: Old Questions and New Insights. Science, 2011, 332, 1519-1523.	12.6	1,780
6	Molecular mediators of hepatic steatosis and liver injury. Journal of Clinical Investigation, 2004, 114, 147-152.	8.2	1,571
7	Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12027-12032.	7.1	1,233
8	Molecular mediators of hepatic steatosis and liver injury. Journal of Clinical Investigation, 2004, 114, 147-152.	8.2	944
9	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 2020, 41, 2313-2330.	2.2	776
10	Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation. Journal of Biological Chemistry, 2007, 282, 18602-18612.	3.4	660
11	Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 5374-5379.	7.1	637
12	Increased Levels of Nuclear SREBP-1c Associated with Fatty Livers in Two Mouse Models of Diabetes Mellitus. Journal of Biological Chemistry, 1999, 274, 30028-30032.	3.4	616
13	Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice. Journal of Clinical Investigation, 2006, 116, 2995-3005.	8.2	587
14	A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. New England Journal of Medicine, 2017, 376, 41-51.	27.0	571
15	Diminished Hepatic Response to Fasting/Refeeding and Liver X Receptor Agonists in Mice with Selective Deficiency of Sterol Regulatory Element-binding Protein-1c. Journal of Biological Chemistry, 2002, 277, 9520-9528.	3.4	563
16	Acetate Dependence of Tumors. Cell, 2014, 159, 1591-1602.	28.9	524
17	PCSK9: a convertase that coordinates LDL catabolism. Journal of Lipid Research, 2009, 50, S172-S177.	4.2	517
18	Molecular biology of PCSK9: its role in LDL metabolism. Trends in Biochemical Sciences, 2007, 32, 71-77.	7.5	512

#	Article	IF	Citations
19	Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver. Journal of Biological Chemistry, 2004, 279, 50630-50638.	3.4	442
20	Nuclear Sterol Regulatory Element-binding Proteins Activate Genes Responsible for the Entire Program of Unsaturated Fatty Acid Biosynthesis in Transgenic Mouse Liver. Journal of Biological Chemistry, 1998, 273, 35299-35306.	3.4	320
21	SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes and Development, 2001, 15, 1206-1216.	5.9	279
22	Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metabolism, 2017, 26, 394-406.e6.	16.2	265
23	The Scap/SREBP Pathway Is Essential for Developing Diabetic Fatty Liver and Carbohydrate-Induced Hypertriglyceridemia in Animals. Cell Metabolism, 2012, 15, 240-246.	16.2	263
24	Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. Journal of Clinical Investigation, 2004, 113, 1168-1175.	8.2	218
25	MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nature Medicine, 2015, 21, 1280-1289.	30.7	203
26	Overexpression of Sterol Regulatory Element-binding Protein-1a in Mouse Adipose Tissue Produces Adipocyte Hypertrophy, Increased Fatty Acid Secretion, and Fatty Liver. Journal of Biological Chemistry, 2003, 278, 36652-36660.	3.4	195
27	Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. Journal of Lipid Research, 2009, 50, 412-423.	4.2	181
28	Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. Journal of Clinical Investigation, 1999, 103, 1067-1076.	8.2	174
29	CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL. Nature Communications, 2016, 7, 10961.	12.8	165
30	Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice. Journal of Lipid Research, 2018, 59, 475-487.	4.2	148
31	Loss of astrocyte cholesterol synthesis disrupts neuronal function and alters whole-body metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 1189-1194.	7.1	143
32	An adipo-biliary-uridine axis that regulates energy homeostasis. Science, 2017, 355, .	12.6	90
33	Expression of SREBP-1c Requires SREBP-2-mediated Generation of a Sterol Ligand for LXR in Livers of Mice. ELife, 2017, 6, .	6.0	82
34	An acetate switch regulates stress erythropoiesis. Nature Medicine, 2014, 20, 1018-1026.	30.7	62
35	Deletion of ELOVL6 blocks the synthesis of oleic acid but does not prevent the development of fatty liver or insulin resistance. Journal of Lipid Research, 2014, 55, 2597-2605.	4.2	61
36	Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice. Journal of Lipid Research, 2017, 58, 1661-1669.	4.2	41

#	Article	IF	Citations
37	AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue. Molecular Metabolism, 2016, 5, 491-505.	6.5	36
38	Hepatocyte toll-like receptor 4 deficiency protects against alcohol-induced fatty liver disease. Molecular Metabolism, 2018, 14, 121-129.	6.5	35
39	Adipocyte Xbp1s overexpression drives uridine production and reduces obesity. Molecular Metabolism, 2018, 11, 1-17.	6.5	34
40	Mogat1 deletion does not ameliorate hepatic steatosis in lipodystrophic (Agpat2â^'/â^') or obese (ob/ob) mice. Journal of Lipid Research, 2016, 57, 616-630.	4.2	29
41	The impact of endotrophin on the progression of chronic liver disease. Experimental and Molecular Medicine, 2020, 52, 1766-1776.	7.7	25
42	Cannabinoid receptor 1 signaling in hepatocytes and stellate cells does not contribute to NAFLD. Journal of Clinical Investigation, 2021, 131, .	8.2	23
43	Unfolding Lipid Metabolism. Science, 2008, 320, 1433-1434.	12.6	11
44	Delisting STAP1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 847-849.	2.4	10
45	CB1Rs in VMH neurons regulate glucose homeostasis but not body weight. American Journal of Physiology - Endocrinology and Metabolism, 2021, 321, E146-E155.	3.5	9
46	Intravascular triglyceride lipolysis becomes crystal clear. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1480-1482.	7.1	7
47	Decreased caveolae in AGPAT2 lacking adipocytes is independent of changes in cholesterol or sphingolipid levels: A whole cell and plasma membrane lipidomic analysis of adipogenesis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166167.	3.8	5
48	Response to Kunos et al. and Lotersztajn and Mallat. Journal of Clinical Investigation, 2022, 132, .	8.2	1
49	Statins Induce Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9. FASEB Journal, 2008, 22, 1040.4.	0.5	0
50	Abstract 61: LXR Agonist Treatment of Nonhuman Primates Increases LDL Cholesterol due to Decreased Hepatic LDL Receptor Expression. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, .	2.4	0